In a patient with panic disorder refractory to at least two adequate trials of selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) and cognitive‑behavioral therapy, how should clomipramine be initiated, dosed, and monitored?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clomipramine for Treatment-Resistant Panic Disorder

In patients with panic disorder refractory to at least two adequate SSRI/SNRI trials plus CBT, clomipramine should be initiated at 25 mg daily, gradually titrated to 100 mg over 2 weeks (divided doses with meals), then increased over several weeks to a maximum of 250 mg daily, with the total daily dose given at bedtime after titration. 1

Rationale for Clomipramine in Treatment-Resistant Panic Disorder

While SSRIs and SNRIs remain first-line pharmacotherapy for panic disorder 2, 3, 4, clomipramine represents a viable option for treatment-resistant cases. Evidence from multiple studies demonstrates clomipramine's efficacy in panic disorder 5, 6, 2, with some data suggesting comparable or superior effectiveness to SSRIs 5. In a comparative trial, clomipramine 75 mg/day achieved a 90% favorable response rate in panic disorder, with faster onset of antipanic effects compared to fluoxetine 5. Another dose-finding study demonstrated that both low and high doses of clomipramine were more efficacious than placebo for panic disorder, with the lower dose being better tolerated and at least as effective 6.

For treatment-refractory panic disorder specifically, clomipramine is explicitly mentioned as an option when patients have not responded to one or more adequate SSRI trials 7. The World Federation of Societies of Biological Psychiatry guidelines recommend clomipramine for obsessive-compulsive disorder and acknowledge TCAs as equally effective to SSRIs for panic disorder, though less well tolerated 2.

Initiation and Titration Protocol

Starting Dose:

  • Begin at 25 mg daily 1
  • Administer in divided doses with meals during initial titration to reduce gastrointestinal side effects 1

Initial Titration (First 2 Weeks):

  • Gradually increase as tolerated to approximately 100 mg daily over the first 2 weeks 1
  • Continue divided dosing with meals during this phase 1

Further Dose Escalation:

  • After the initial 2 weeks, increase gradually over several weeks 1
  • Maximum dose: 250 mg daily in adults 1
  • After titration is complete, the total daily dose may be given once daily at bedtime to minimize daytime sedation 1

Important Timing Consideration: Steady-state plasma levels may not be achieved until 2-3 weeks after dosage changes due to the long elimination half-lives of clomipramine and its active metabolite, desmethylclomipramine 1. Therefore, wait 2-3 weeks between further dosage adjustments after the initial titration phase.

Critical Monitoring Requirements

Seizure Risk (Most Significant Concern): The cumulative incidence of seizures with clomipramine at doses up to 300 mg/day was 0.64% at 90 days, 1.12% at 180 days, and 1.45% at 365 days 1. The daily dose must be limited to a maximum of 250 mg in adults 1. Exercise particular caution in patients with:

  • History of seizures
  • Brain damage of any etiology
  • Alcoholism
  • Concomitant use of drugs that lower seizure threshold 1

Counsel patients about the risk of sudden loss of consciousness during activities like driving, operating machinery, swimming, or climbing 1.

Serotonin Syndrome: Monitor closely for serotonin syndrome, particularly when combining with other serotonergic agents 1. Symptoms include:

  • Mental status changes (agitation, hallucinations, delirium, coma)
  • Autonomic instability (tachycardia, labile blood pressure, diaphoresis, flushing, hyperthermia)
  • Neuromuscular changes (tremor, rigidity, myoclonus, hyperreflexia)
  • Gastrointestinal symptoms (nausea, vomiting, diarrhea) 1

Contraindicated combinations:

  • MAOIs intended to treat psychiatric disorders (allow at least 14 days between discontinuing an MAOI and starting clomipramine, and vice versa) 1
  • Linezolid or intravenous methylene blue 1

Suicidality Monitoring: Monitor for emergence of suicidal thinking and behavior, particularly in patients under age 25 1. Also monitor for behavioral activation, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania 1.

Cardiovascular Monitoring: TCAs can cause cardiac conduction abnormalities 8. Baseline and periodic ECG monitoring is prudent, particularly in patients with cardiac disease.

Other Adverse Effects to Monitor:

  • Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision)
  • Orthostatic hypotension
  • Weight gain
  • Sexual dysfunction
  • Angle-closure glaucoma (avoid in patients with anatomically narrow angles without patent iridectomy) 1
  • DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) - discontinue immediately if this occurs 1

Duration of Treatment

While there are no systematic studies definitively answering how long to continue clomipramine for panic disorder, the condition is chronic and continuation for responding patients is reasonable 1. One study suggested that treatment duration should be at least 10 weeks rather than 6 weeks 5. Patients have been continued on clomipramine under double-blind conditions for up to 1 year without loss of benefit 1. Dosage adjustments should maintain patients on the lowest effective dosage, with periodic reassessment to determine ongoing need for treatment 1.

Common Pitfalls to Avoid

  1. Inadequate trial duration: Ensure at least 6-8 weeks at maximum tolerated dose before declaring treatment failure, accounting for the 2-3 week delay to steady state after dose changes 1

  2. Premature dose escalation: Rapid titration increases risk of intolerable side effects and dropout. The gradual titration schedule exists specifically to permit tolerance development 1

  3. Ignoring drug interactions: Clomipramine has significant potential for drug-drug interactions, particularly with other serotonergic agents, drugs metabolized by cytochrome P450 enzymes, and drugs that lower seizure threshold 9, 1

  4. Failure to consolidate dosing: After successful titration, switching to once-daily bedtime dosing improves adherence and minimizes daytime sedation 1

  5. Abrupt discontinuation: Taper clomipramine when discontinuing to avoid withdrawal symptoms, similar to other antidepressants 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.